Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Item
http://www.wikidata.org/entity/Q38870282
Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.CDK4/6 blockade in breast cancer: current experience and future perspectives.Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once ThoughtA paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitorsThe potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
P2860

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Item
http://www.wikidata.org/entity/Q38870282
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Ribociclib (LEE011): Mechanism ...... bitor in Various Solid Tumors.
@en
type
label
Ribociclib (LEE011): Mechanism ...... bitor in Various Solid Tumors.
@en
prefLabel
Ribociclib (LEE011): Mechanism ...... bitor in Various Solid Tumors.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
Ribociclib (LEE011): Mechanism ...... bitor in Various Solid Tumors.
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-16-3157
P407
P433
P478
P577
P698
P932